Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | TGM1 | P22735 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 2/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16403549 | 0.81 | CHEK1 (0.44) | IKBKECHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL18549584 | 0.76 | CHEK1 (0.40) | IKBKECHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL27667199 | 0.76 | CHEK1 (0.40) | IKBKECHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL1623706 | 0.75 | NPC1 (0.39) | IKBKECHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL1623506 | 0.74 | KDM4E (0.42) | IKBKECHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL27667081 | 0.73 | GFER (0.30) | — | |
| SCHEMBL24164160 | 0.73 | PKM (0.31) | — | |
| SCHEMBL18555134 | 0.73 | CHEK1 (0.38) | IKBKECHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL1623420 | 0.69 | CHEK1 (0.45) | IKBKECHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL3525570 | 0.67 | CHEK1 (0.54) | IKBKECHEK1AURKADAPK3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | IKBKE 195/4885CHEK1 520/4885AURKA 593/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | IKBKE 3922/4885CHEK1 4336/4885AURKA 4715/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | IKBKE 3922/4885CHEK1 4336/4885AURKA 4715/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | IKBKE 172/4885CHEK1 689/4885AURKA 813/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | IKBKE 3922/4885CHEK1 4336/4885AURKA 4715/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | IKBKE 4084/4885CHEK1 3830/4885AURKA 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.